gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Purinergic receptor P2Y, G-protein coupled, 12

P2Y12, platelet ADP receptor
The product of this gene belongs to the family of G-protein coupled receptors. This family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. This receptor is involved in platelets aggregation, and is a potential target for the treatment of thromboembolisms and other clotting disorders. Two transcript variants encoding the same isoform have been identified for this gene. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: HAD, CAN, iMpact, P2Y, ACID
Papers on P2Y12
Heparin Versus Bivalirudin Monotherapy in the Setting of Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction.
Review
New
Finks et al., Raleigh, United States. In Ann Pharmacother, Feb 2016
The evidence available is complicated by variances in use of glycoprotein IIb/IIIa inhibitors (GPIs), P2Y12 inhibitors, access sites, and anticoagulant dosing strategies.
Cangrelor-Mediated Cardioprotection Requires Platelets and Sphingosine Phosphorylation.
New
Downey et al., Mobile, United States. In Cardiovasc Drugs Ther, Feb 2016
UNASSIGNED: In animal models platelet P2Y12 receptor antagonists put the heart into a protected state, not as a result of suppressed thrombosis but rather through protective signaling, similar to that for ischemic postconditioning.
Antithromboembolic strategies in atrial fibrillation: A review.
New
Jerie et al., Bologna, Italy. In Cardiol J, Feb 2016
The impact of used stents and novel P2Y12 antagonist-antiplatelets and duration of triple therapy is discussed.
Assessment of platelet-derived thrombogenicity by the total thrombus-formation analysis system in coronary artery disease patients on antiplatelet therapy.
New
Ogawa et al., Kumamoto, Japan. In J Thromb Haemost, Feb 2016
The on-clopidogrel platelet aggregation was measured by P2Y12 reaction units (PRU) using the VerifyNow(®) system.
Effects of P2Y12 receptor antagonists beyond platelet inhibition - comparison of ticagrelor with thienopyridines.
Review
New
Schulz et al., Mölndal, Sweden. In Br J Pharmacol, Feb 2016
UNASSIGNED: The effect and clinical benefit of P2Y12 receptor antagonists may not be limited to platelet inhibition and the prevention of arterial thrombus formation.
Treatment and outcomes of patients with recurrent myocardial infarction: A prospective observational cohort study.
New
Erne et al., Zürich, Switzerland. In J Cardiol, Feb 2016
P2Y12 inhibitors (76% vs. 83%; p<0.001), or statins (73% vs. 77%; p<0.001), or undergo primary percutaneous coronary intervention (77% vs. 87%; p<0.001).
Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease.
Review
New
Maddox et al., Aurora, United States. In Curr Atheroscler Rep, Jan 2016
Dual antiplatelet therapy (DAPT) is the use of a P2Y12 receptor antagonist (clopidogrel, prasugrel, or ticagrelor) in combination with aspirin.
An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention.
Review
New
Rao et al., Memphis, United States. In Am Heart J, Jan 2016
Moderator analyses examined the impact of routine use of GPI, radial access, and P2Y12 inhibitors on safety outcomes.
Randomized Comparison of Different Thienopyridine Loading Strategies in Patients Undergoing Elective Coronary Intervention: The ExcelsiorLOAD Trial.
New
Valina et al., Freiburg, Germany. In Jacc Cardiovasc Interv, Jan 2016
METHODS: We randomly assigned 300 P2Y12 receptor blocker-naive patients undergoing an elective PCI to loading with clopidogrel 600 mg, prasugrel 30 mg, or prasugrel 60 mg immediately before the PCI.
Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?
Review
New
Berger et al., München, Germany. In Eur Heart J, Jan 2016
UNASSIGNED: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the mainstay of treatment for acute coronary syndrome (ACS) patients, whether they undergo a percutaneous coronary intervention (PCI) or are managed medically.
Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas with Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit.
New
Impact
Hanahan et al., Lausanne, Switzerland. In Cancer Cell, Nov 2015
The anticoagulant ticlopidine, which inhibits the purinergic receptor P2Y12, potentiated imipramine, elevating cAMP, a modulator of autophagy, reducing cell viability in culture, and increasing survival in glioma-bearing mice.
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes.
Review
New
Impact
Steg et al., Boston, United States. In Lancet, Aug 2015
The landmark CURE trial showed that the addition of a P2Y12 antagonist, clopidogrel, to aspirin was beneficial in the treatment of acute coronary syndromes.
Long-term use of ticagrelor in patients with prior myocardial infarction.
New
Impact
PEGASUS-TIMI 54 Steering Committee and Investigators et al., Macao. In N Engl J Med, Jun 2015
We investigated the efficacy and safety of ticagrelor, a P2Y12 receptor antagonist with established efficacy after an acute coronary syndrome, in this context.
Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis.
Review
New
Impact
Yeh et al., Boston, United States. In Lancet, Mar 2015
BACKGROUND: Treatment with aspirin and a P2Y12 inhibitor is commonly used in patients with cardiovascular disorders.
New approaches to inhibiting platelets and coagulation.
Review
Impact
Bhatt et al., Boston, United States. In Annu Rev Pharmacol Toxicol, 2014
Development of new oral and intravenous adenosine diphosphate P2Y12 inhibitors and novel antiplatelet agents continues to transform the landscape of antiplatelet therapy.
Roles of purinergic receptor P2Y, G protein-coupled 12 in the development of atherosclerosis in apolipoprotein E-deficient mice.
GeneRIF
Liu et al., Shanghai, China. In Arterioscler Thromb Vasc Biol, 2012
P2Y12 modulates atherogenesis, at least in part by augmenting inflammatory cell recruitment via regulation of platelet alpha-granule release.
Fractalkine activates a signal transduction pathway similar to P2Y12 and is associated with impaired clopidogrel responsiveness.
GeneRIF
Schäfer et al., Hannover, Germany. In Arterioscler Thromb Vasc Biol, 2012
increased fractalkine levels are associated with decreased endogenous platelet inhibition and impaired response to P2Y12 inhibition with clopidogrel.
Arrestin scaffolds NHERF1 to the P2Y12 receptor to regulate receptor internalization.
GeneRIF
Mundell et al., Bristol, United Kingdom. In J Biol Chem, 2012
Findings suggest a novel model by which arrestin can serve as an adaptor to promote NHERF1 interaction with a GPCR to facilitate effective NHERF1-dependent receptor internalization.
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
GeneRIF
INNOVATE-PCI Investigators et al., Edmonton, Canada. In Circ Cardiovasc Interv, 2012
In patients undergoing nonurgent percutaneous coronary intervention intravenous/oral P2Y12 inhibitor elinogrel did not significantly increase thrombolysis in myocardial infarction or bleeding.
Combined blockade of ADP receptors and PI3-kinase p110β fully prevents platelet and leukocyte activation during hypothermic extracorporeal circulation.
GeneRIF
Straub et al., Tübingen, Germany. In Plos One, 2011
Combined blockade of P2Y12, P2Y1 and PI3-kinase p110beta fully prevents platelet and leukocyte activation during hypothermic extracorporeal circulation.
share on facebooktweetadd +1mail to friends